BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31017020)

  • 1. TOXview: a novel graphical presentation of cancer treatment toxicity profiles.
    Ngai LL; Ter Veer E; van den Boorn HG; van Herk EH; van Kleef JJ; van Oijen MGH; van Laarhoven HWM
    Acta Oncol; 2019 Aug; 58(8):1138-1148. PubMed ID: 31017020
    [No Abstract]   [Full Text] [Related]  

  • 2. The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
    Ter Veer E; Haj Mohammad N; van Valkenhoef G; Ngai LL; Mali RMA; Anderegg MC; van Oijen MGH; van Laarhoven HWM
    J Natl Cancer Inst; 2016 Oct; 108(10):. PubMed ID: 27576566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis.
    van Kleef JJ; Ter Veer E; van den Boorn HG; Schokker S; Ngai LL; Prins MJ; Mohammad NH; van de Poll-Franse LV; Zwinderman AH; van Oijen MGH; Sprangers MAG; van Laarhoven HWM
    J Natl Cancer Inst; 2020 Jan; 112(1):12-29. PubMed ID: 31251346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis.
    van den Ende T; Abe Nijenhuis FA; van den Boorn HG; Ter Veer E; Hulshof MCCM; Gisbertz SS; van Oijen MGH; van Laarhoven HWM
    Front Oncol; 2019; 9():684. PubMed ID: 31403035
    [No Abstract]   [Full Text] [Related]  

  • 5. Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry.
    Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Sánchez Cánovas M; Hernández R; Pericay C; Echavarria I; Lacalle A; Visa L; Rodríguez Palomo A; Mangas M; Cano JM; Buxo E; Álvarez-Manceñido F; García T; Lorenzo JE; Ferrer-Cardona M; Viudez A; Azkarate A; Ramchandani A; Arias D; Longo F; López C; Sánchez Bayona R; Limón ML; Díaz-Serrano A; Fernández Montes A; Sala P; Cerdá P; Rivera F; Gallego J;
    Gastric Cancer; 2018 Jan; 21(1):96-105. PubMed ID: 28393278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study.
    Dijksterhuis WPM; Verhoeven RHA; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
    Int J Cancer; 2020 Apr; 146(7):1889-1901. PubMed ID: 31340065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triplet versus doublet combination regimens for the treatment of relapsed or refractory multiple myeloma: A meta-analysis of phase III randomized controlled trials.
    Sun Z; Zheng F; Wu S; Liu Y; Guo H; Liu Y
    Crit Rev Oncol Hematol; 2017 May; 113():249-255. PubMed ID: 28427514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of AferBio® on quality of life and chemotherapy toxicity in advanced lung cancer patients (AFERBIO study): protocol study for a phase II randomized controlled trial.
    D'Almeida Preto D; Baston MT; Geraige CC; Augusto SB; de Oliveira MA; Mamere AE; Pinto GDJ; Dias JM; De Marchi PRM; Paiva BSR; Paiva CE
    BMC Cancer; 2019 Apr; 19(1):382. PubMed ID: 31023257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
    Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials.
    Davidson M; Wagner AD; Kouvelakis K; Nanji H; Starling N; Chau I; Watkins D; Rao S; Peckitt C; Cunningham D
    Eur J Cancer; 2019 Nov; 121():40-47. PubMed ID: 31542640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis.
    Ter Veer E; Creemers A; de Waal L; van Oijen MGH; van Laarhoven HWM
    Int J Cancer; 2018 Jul; 143(2):438-448. PubMed ID: 29451302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care.
    Meulendijks D; van Hasselt JGC; Huitema ADR; van Tinteren H; Deenen MJ; Beijnen JH; Cats A; Schellens JHM
    Eur J Cancer; 2016 Feb; 54():120-130. PubMed ID: 26761784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z
    Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endostar (rh-endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell lung cancer: A meta-analysis.
    An J; Lv W
    Thorac Cancer; 2018 May; 9(5):606-612. PubMed ID: 29575575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Nishijima TF; Shachar SS; Nyrop KA; Muss HB
    Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARG Toxicity Score with oncologists' estimates of toxicity based on clinical judgement.
    Moth EB; Kiely BE; Stefanic N; Naganathan V; Martin A; Grimison P; Stockler MR; Beale P; Blinman P
    J Geriatr Oncol; 2019 Mar; 10(2):202-209. PubMed ID: 30224184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis.
    Sher AF; Golshani GM; Wu S
    Cancer Invest; 2020 Feb; 38(2):130-138. PubMed ID: 31985314
    [No Abstract]   [Full Text] [Related]  

  • 20. Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review.
    Winquist E; Agbassi C; Meyers BM; Yoo J; Chan KKW;
    J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):29. PubMed ID: 28376866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.